Navigation Links
YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
Date:8/10/2009

titled 'Changing Cuba Policy - In the United States' National Interest,' which recommended pharmaceutical imports from Cuba's rapidly developing biotech industry. We are most appreciative of the extensive support we have received for our application from SCFR Chairman Senator John Kerry (D-MA), Western Hemisphere Subcommittee Chairman Senator Chris Dodd (D-CT) and SCFR Ranking Member Senator Richard Lugar (R-IN) and for their acute understanding of the needs of cancer patients. Such licenses have been previously granted to two companies seeking to commercialize Cuban-origin therapeutics in the US and we have ongoing discussions with OFAC in this regard."

YM USA previously received a license from OFAC to import nimotuzumab into the US to conduct a study of nimotuzumab in children suffering from recurrent diffuse intrinsic pontine glioma. This trial is ongoing at 10 of the principal oncology hospitals in the US and data is expected in 2010. Nimotuzumab is also available on a compassionate use basis in the US for children with this condition and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. The drug has demonstrated efficacy in clinical trials without the serious side effects observed with the marketed EGFR-targeting drugs. Nimotuzumab has been administered to approximately 5,000 patients worldwide and is currently in 32 trials internationally of which 11 are being conducted by YM and its four licensees. Three of the latter are Phase III trials, including one being conducted by the internationally recognized National Cancer Center of Singapore, which selected nimotuzumab over the alternative antibodies because of its benign side effect profile.


'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Second Quarter 2009 Results
3. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
4. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
8. Regado Biosciences Expands Medical Advisory Board
9. YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
10. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
11. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... guards came to the DHS Science and Technology Directorates ... was an emergency escape hood worthy of James Bond: a ... folding to the dimensions of a DVD case, and donnable ... be maintenance-free, filter nerve, blood, and blister agents, remove toxic ...
... Today at 5:00 p.m., CAMBRIDGE, Mass., April 21 ... the FDA has informed the,company of its opinion that ... Myozyme produced at the 2000L scale should be,classified as ... of the molecules. Currently, Genzyme has U.S.,approval to sell ...
... Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, PITTSBURGH, April 21 ... campaign,for the new TUMS(R) QuikPak(TM), the first and only instant ... part of,a larger new "Bring It On" brand strategy designed ...
Cached Biology Technology:Boys in the Hood 2Genzyme Provides Update on Myozyme(R) Manufacturing 2Genzyme Provides Update on Myozyme(R) Manufacturing 3Genzyme Provides Update on Myozyme(R) Manufacturing 4Genzyme Provides Update on Myozyme(R) Manufacturing 5New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... season almost upon us and increasing concerns about ... pickups, it is timely that researchers should turn ... Writing in a forthcoming issue of the Inderscience ... Management, researchers suggest a new approach to cutting ...
... the Commission for Environmental Cooperation (CEC) reveals that a ... environment15 percent for the United States and Canada from ... industrial facilities that are the largest generators of emissions. ... leading role of the largest waste-producing facilities stands in ...
... State University and the University of Bucharest, Romania, ... dobrogea in eastern Romania. Previously unexamined, these ancient ... 150 million years ago during the Jurassic period. ... determine various aspects of biodiversity and patterns of ...
Cached Biology News:Computer solution to delivery problem 2Toxic releases down from North American industry leaders, increasing from other facilities 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
Bovine Calf Serum...
Collected from animals of U.S. origin.Collected from animals of U.S. origin. *Can be used in cell growth studies and immunoassays. *Sterility tested, * Mycoplasma tested upon request, *Endoto...
Biology Products: